Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare


Charles River Discovery




Silicon Biosystems   




  View All Sponsors 

Final Agenda 


Cancer Biologics 

Day 1  |  Day 2  |  Day 3  |  Download Brochure 

Recommended Pre-Conference Short Course * 

(SC4) Identification, Characterization and Targeting of Cancer Stem Cells 


*Separate Registration Required. 


Wednesday, February 23 

7:00 am Registration and Morning Coffee

8:00 Plenary Keynotes - Details 

9:40 Grand Opening Refreshment Break in the Exhibit Hall




11:00 Chairperson’s Opening Remarks

Gregory P. Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center

11:10 Tumor Penetration of Therapeutic Antibodies–Implications for Cancer Therapy

David BlakeyDavid Blakey, Ph.D., Chief Scientist, Oncology Discovery, AstraZeneca

The ability of intact antibodies and fragments to access tumor cells distant from the tumor blood supply is an important therapeutic consideration for antibody based oncology drugs. Pre-clinical and clinical data on antibody distribution within tumors will be reviewed and the implications for therapy will be discussed.


11:40 The Influence of Affinity and Internalization on Tumor Targeting and Penetration of Antibodies     

Gregory P. Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center

While a number of antibodies have been licensed for the treatment of cancer, the affinity associated with optimal targeting and penetration of solid tumors has yet to be determined. We will present our studies employing a panel of anti-HER2 human IgG molecules that bind over a range of affinities to the identical epitope on HER2 and discuss the impact of affinity and antigen-mediated internalization on targeting and penetration.


12:10 pm Opportunities and Challenges in the Development of Targeted Nanomedicines 

Theresa AllenTheresa M. Allen, Ph.D., Division Chair, Drug Delivery, Centre for Drug Research & Development; Professor Emeritus, Pharmacology & Oncology, University of Alberta

Several passively targeted nanomedicines (PTN) have received clinical approval. Ligand-targeted nanomedicines (LTN) that deliver drugs, including siRNAs, selectively to target cells, may, or may not, improve therapeutic responses versus PTN, depending on a variety of factors.  Improvements in outcomes for LTN must be of sufficient magnitude to compensate for the additional complexities (equals increased costs) involved in their development.


12:40 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

1:45 Dessert in the Exhibit Hall

2:15 Chairperson’s Remarks

Theresa M. Allen, Ph.D., Division Chair, Drug Delivery, Centre for Drug Research & Development; Professor Emeritus, Pharmacology & Oncology, University of Alberta

2:20 Therapeutic Cell Engineering Using Cell Surface-Conjugated Synthetic Nanoparticles

Darrell J. Irvine, Associate Professor, Massachusetts Institute of Technology; Koch Institute for Integrative Cancer Research; Ragon Institute of MGH, MIT, and Harvard; Howard Hughes Medical Institute

An approach to enhance adoptive T-cell therapy of cancer and other cell therapies will be described, based on the direct conjugation of drug-loaded nanoparticles to the surface of therapeutic cells.  We show how this approach dramatically enhances the potency of cytokine or small-molecule adjuvant drugs, using dosages that have no effect when given by traditional systemic routes.

2:50 Understanding Key Delivery Aspects Controlling the Therapeutic Window of MM-302: HER2-Targeted Liposomal Doxorubicin

Bart Hendriks, Ph.D., Associate Director and Research Team Leader, MM-302, Merrimack Pharmaceuticals

MM-302 is the first of a new of nanoparticle drugs that is designed to deliver the cytotoxic drug, doxorubicin, specifically to tumor types that over-express the Her2 receptor. Pre-clinical data and mathematical modeling approaches have been used to demonstrate how HER2 levels and vascular parameters are key factors that control the delivery of MM-302 to target and non-target cells.

3:20 POSTER SPOTLIGHT: Targeting the Transforming Growth Factor-Beta (TGF-Beta) Family: A New Generation of Cancer Therapeutic

John Zwaagstra, National Research Council of Canada

3:50 Sponsored Presentations (Opportunities Available)  

4:20 Reception in the Exhibit Hall (Sponsorship Available) 

5:20 Breakout Discussions in the Exhibit Hall

Concurrent Problem Solving Break-Out Sessions are interactive, problem solving discussions hosted by a moderator to discuss a topic in depth.  The discussions are open to all attendees, sponsors, exhibitors, and speakers and provide a forum for discussing key issues and meeting potential partners. Please pick a topic of your choice and join in. 

Clinical and Regulatory Strategies to Optimize the Development Process for Cancer Biotherapeutics

Moderator: Yu-Waye Chu, Ph.D., Product Development, Oncology, Genentech, Inc.


  • Ideal patient population for immunotherapeutics
  • Adaptive trial designs
  • Challenges with toxicity and safety
  • Regulatory considerations

Challenges of Developing Antibody-Drug Conjugates

Moderator: Puja Sapra, Ph.D., Director, Bioconjugates, Oncology Research Unit, Pfizer, Inc.

  • Selecting the size/PK balance for optimal tumor penetration and reduced clearance
  • Strategies to identify “ cleaner” targets
  • How the target biology impacts on the type of linker and product selected
  • Issues regarding selection of payloads
  • Issues regarding the safety profile and minimizing liver toxicity

Challenges of Targeting Cancer Stem Cells

Moderator: Norman J. Maitland, Ph.D., CSO, Procure Therapeutics Ltd.

  • Approaches to the identification and evaluation of new cancer stem cell targets
  • Payloads that overcome the enhanced resistance of cancer stem cells
  • Potential safety issues
  • Strategy for entering clinical trials

Cost/Benefit Ratio of New Treatments for Cancer

Moderator: Theresa M. Allen, Ph.D., Division Chair, Drug Delivery, Centre for Drug Research & Development; Professor Emeritus, Pharmacology & Oncology, University of Alberta

  • Are the costs beginning to exceed the benefits? Are these costs limiting access?  Will this prevent their approval or sales in countries other than the USA?
  • What would be an appropriate balance between the costs and benefits of new therapies:  Are there guidelines for this? Should there be guidelines?
  • Improved quality of life is often not incorporated into cost/benefit analyses.  How could this be approached?

Antibodies versus Alternative Scaffolds: Pros and Cons

Moderator: David Blakey, Ph.D., Chief Scientist, Oncology Discovery, AstraZeneca

  • Focus on tumor penetration, specificity, half-life and toxic load
  • Weighing up Fc-effector function versus immunological side effects
  • Small immunoglobulin fragments versus alternative scaffolds
  • Challenges with manufacturing and intellectual property

6:20 Close of Day

Day 1  |  Day 2  |  Day 3  |  Download Brochure